跳至主要内容
临床试验/NCT07572929
NCT07572929尚未招募2 期

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

Medical College of Wisconsin1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2026年8月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
尚未招募
入组人数
450
试验地点
1

研究概览

简要总结

This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and/or molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years at time of transplant.
  • Must have a diagnosis of a myeloid malignancy, myelodysplastic syndrome, myeloproliferative neoplasm (including primary or secondary myelofibrosis), or acute myeloid leukemia or biphenotypic acute leukemia.
  • Pre-transplant disease assessment must include at least one:
  • Immunophenotypic assessment by flow for aberrant blasts
  • NGS to identify persistence of malignant clones using a standard clinically available assay
  • PCR based measurement of prior identified mutations (if applicable)
  • Ability to understand a written informed consent document, and the willingness to sign it.

排除标准

  • 未提供

研究组 & 干预措施

MRD negative

Active Comparator

MRD negative patients assigned to Arm B will receive no intervention.

干预措施: No intervention (Other)

MRD positive

Active Comparator

MRD positive patients assigned to Arm A are required to initiate maintenance therapy on this study. Maintenance therapy will be suggested by the PIs, however final choice of maintenance is at the discretion of the treating physician.

干预措施: Maintenance Therapy (Drug)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sameem M. Abedin, MD

Associate Professor

Medical College of Wisconsin

研究点 (1)

Loading locations...

相似试验